Revolution Medicines Inc
1RVMD
Company Profile
Business description
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
Contact
700 Saginaw Drive
Redwood CityCA94063
USAT: +1 650 481-6801
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
700
Stocks News & Analysis
stocks
Is this still an ASX share to own forever?
Find out how this defensive player has fared after earnings.
stocks
After earnings, is Nvidia stock a buy, a sell, or fairly valued?
No signs of a slowdown in demand for Nvidia’s chips, and the long-term picture looks bright.
stocks
Short-term pain for long-term gain for undervalued ASX share
Cost reductions lower our profit estimates but should lead to improved long-term outcomes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,089.70 | 49.50 | 0.55% |
| CAC 40 | 7,719.71 | 65.46 | 0.86% |
| DAX 40 | 23,594.80 | 107.47 | 0.46% |
| Dow JONES (US) | 45,271.23 | 24.58 | -0.05% |
| FTSE 100 | 9,177.99 | 61.30 | 0.67% |
| HKSE | 25,068.30 | 275.13 | -1.09% |
| NASDAQ | 21,497.73 | 218.10 | 1.02% |
| Nikkei 225 | 42,581.85 | 642.96 | 1.53% |
| NZX 50 Index | 13,133.20 | 58.39 | 0.45% |
| S&P 500 | 6,448.26 | 32.72 | 0.51% |
| S&P/ASX 200 | 8,823.50 | 56.20 | 0.64% |
| SSE Composite Index | 3,758.71 | 54.85 | -1.44% |